Home » News » Vasgen Receives Grant for US Patent and Advances R&D Operations

Vasgen Receives Grant for US Patent and Advances R&D Operations

London UK, 3rd February 2015: Vasgen Limited (“Vasgen” or “the Company”), a new speciality biotech company, reports that the United States Patent and Trademark Organisation (USPTO) has issued a notice of allowance for the US patent entitled “ADAM15 Antibodies and Immunogenic Peptides.”

Vasgen is developing a monoclonal antibody therapy targeting ADAM15 for the treatment of ocular neovascular diseases such as wet age-related macular degeneration and potentially several aggressive cancers. The company has recently embarked upon an Innovate UK Biomedical Catalyst funded project in collaboration with the UCL Institute of Ophthalmology to evaluate early-stage therapeutic candidates.

Dr Salman Rahman, CEO and co-founder of Vasgen said:The news of the allowance of our first patent by the USPTO represents a milestone for our company and our ambition to develop monoclonal antibody therapies targeting ADAM15 for the treatment of ocular neovascular diseases and cancer. We hope this will be the first of several patents protecting our company’s technologies necessary for the development of further therapeutic programmes.”

Dr Yatin Patel, COO and co-founder of Vasgen said: This news confirms the uniqueness of our technology for targeting ADAM15 as a potential first-in-class anti-angiogenesis therapy. Therefore, this development is an important milestone for Vasgen coinciding with the progression of our R & D activities.”

-Ends-

Notes to Editors:

Vasgen Ltd

Vasgen Limited is a new London-based biotech company developing innovative ocular and cancer therapeutics to meet unmet clinical needs.

The Company’s technologies include AbIMP®, a novel discovery platform that utilises antibodies as selective inhibitors of previously intractable metzincin protease targets, with a particular focus on the ADAMs gene family. The Company’s lead product under development is a pre-clinical stage therapeutic AbIMP targeting ADAM15 for anti-angiogenesis therapy. More information is available at www.vasgen.co.uk

For further information please contact:

Tel : +44 (0)207 691 2149

info@vasgen.co.uk